pharmaphorum: Wegovy pill lifts Novo outlook as CagriSema eyed for 2027
Novo reported about DKK 5.39bn ($813m) in Wegovy pill sales across the US, UAE, UK and Germany in Q3, helping it raise 2026 guidance while injectable Wegovy and Ozempic lost share to tirzepatide. CEO Mike Doustdar also flagged a possible early-2027 US launch of CagriSema if FDA approval comes before year-end.
Source: pharmaphorum (4 Nov 2026). Image: pharmaphorum.